Mechanistic insight on the role of iRhom2-TNF-α-BAFF signaling pathway in various autoimmune disorders
- PMID: 38151421
- DOI: 10.1016/j.jbior.2023.101011
Mechanistic insight on the role of iRhom2-TNF-α-BAFF signaling pathway in various autoimmune disorders
Abstract
iRhom2 is a crucial cofactor involved in upregulation of TNF receptors (TNFRs) and the pro-inflammatory cytokine tumor necrosis factor (TNF-) from the cell surface by ADAM17. Tumor necrosis factor- α converting enzyme (TACE) is another name given to ADAM17. Many membrane attached biologically active molecules are cleaved by this enzyme which includes TNFRs and the pro-inflammatory cytokine tumor necrosis factor- α. The TNF receptors are of two types TNFR1 and TNFR2. iRhom2 belongs to the pseudo-protease class of rhomboid family, its abundance is observed in the immune cells. Biological activity of ADAM17 is affected in multiple levels by the iRhom2. ADAM17 is trafficked into the Golgi apparatus by the action of iRhom2, where it gets matured proteolytically and is stimulated to perform its function on the cell surface. This process of activation of ADAM17 results in the protection of the organism from the cascade of inflammatory reactions, as this activation blocks the TNF- α mediated secretion responsible for inflammatory responses produced. Present paper illustrates about the iRhom2-TNF-α-BAFF signaling pathway and its correlation with several autoimmune disorders such as Rheumatoid Arthritis, Systemic Lupus Erythematosus, Hemophilia Arthropathy, Alzheimer's disease and Tylosis with esophageal cancer etc.
Keywords: Autoimmune diseases; BAFF signaling; TNF-α; iRhom1 and iRhom2 receptors; iRhom2.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.Blood. 2018 Sep 6;132(10):1064-1074. doi: 10.1182/blood-2017-12-820571. Epub 2018 May 18. Blood. 2018. PMID: 29776906 Free PMC article.
-
Cryo-EM reveals that iRhom2 restrains ADAM17 protease activity to control the release of growth factor and inflammatory signals.Mol Cell. 2024 Jun 6;84(11):2152-2165.e5. doi: 10.1016/j.molcel.2024.04.025. Epub 2024 May 22. Mol Cell. 2024. PMID: 38781971 Free PMC article.
-
ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).J Biol Chem. 2020 Mar 27;295(13):4350-4358. doi: 10.1074/jbc.RA119.011136. Epub 2020 Feb 14. J Biol Chem. 2020. PMID: 32060096 Free PMC article.
-
iRhom2: An Emerging Adaptor Regulating Immunity and Disease.Int J Mol Sci. 2020 Sep 8;21(18):6570. doi: 10.3390/ijms21186570. Int J Mol Sci. 2020. PMID: 32911849 Free PMC article. Review.
-
With blood in the joint - what happens next? Could activation of a pro-inflammatory signalling axis leading to iRhom2/TNFα-convertase-dependent release of TNFα contribute to haemophilic arthropathy?Haemophilia. 2014 May;20 Suppl 4:11-4. doi: 10.1111/hae.12416. Haemophilia. 2014. PMID: 24762269 Review.
Cited by
-
Differential genes expression of immune tolerance induction in hemophilia A: an exploratory RNA-seq test from a Chinese hemophilia comprehensive care centre.Transl Pediatr. 2024 Dec 31;13(12):2110-2117. doi: 10.21037/tp-24-300. Epub 2024 Dec 27. Transl Pediatr. 2024. PMID: 39823014 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous